Elemental Diet as a Therapeutic Modality: A Comprehensive Review
- PMID: 39001958
- PMCID: PMC11415405
- DOI: 10.1007/s10620-024-08543-1
Elemental Diet as a Therapeutic Modality: A Comprehensive Review
Abstract
Elemental diets have been employed for the management of various diseases for over 50 years, with several mechanisms mediating their beneficial effects. Yet, they are underutilized due to poor palatability, access, cost, and lack of awareness regarding their clinical efficacy. Therefore, in this review, we aimed to systematically search and review the literature to summarize the formulation variability, mechanisms of action, clinical applications, and tolerability of the elemental diets in gastrointestinal diseases. While large prospective trials are lacking, elemental diets appear to exhibit objective and subjective clinical benefit in several diseases, including eosinophilic esophagitis, eosinophilic gastroenteritis, inflammatory bowel diseases, small intestinal bacterial overgrowth, intestinal methanogen overgrowth, chemoradiotherapy-associated mucositis, and celiac disease. Although some data support the long-term use of elemental diets as an add-on supplement for chronic pancreatitis and Crohn's disease, most of the literature on exclusive elemental diets focuses on inducing remission. Therefore, subsequent treatment strategies for maintaining remission need to be adopted in chronic/relapsing diseases. Several mechanistic pathways were identified to mediate the effects of elemental diets, including food additive and allergen-free content, high passive absorption rate, and anti-inflammatory properties. High rates of intolerance up to 40% are seen in the trials where exclusive elemental diets were administered orally due to poor organoleptic acceptability; however, when tolerated, adverse events were rare. Other limitations of elemental diets are cost, access, and lifestyle/social restrictions. Moreover, judicious use is advised in presence of a concomitant restrictive food intake disorders. Elemental diets offer a potentially highly efficacious dietary intervention with minor side effects. Palatability, cost, access, and social restrictions are common barriers of use. Prospective clinical trials are needed to elucidate the role of elemental formulas in the management of individual diseases.
Keywords: Crohn’s disease; Elemental diet; Enteral nutrition; Eosinophilic esophagitis; Intestinal methanogen overgrowth; Small intestinal bacterial overgrowth.
© 2024. The Author(s).
Conflict of interest statement
MP is a consultant for Ferring Pharmaceuticals, Inc, Salvo Health, Dieta Health, and Vivante Health, Inc has received grant support from Bausch Health, and has equity in Gemelli Biotech, Dieta Health, Salvo Health, Vivante Health, and Good LFE. RM has equity in Gemelli Biotech and Good LFE. AR is a consultant/speaker for Bausch Health and has equity in Gemelli Biotech and Good LFE. Cedars-Sinai has licensing agreements with Hobbs Medical and Gemelli Biotech. All other authors report no conflicts of interest.
Figures
References
-
- Koretz RL, Meyer JH. Elemental diets–facts and fantasies. Gastroenterology. 1980Feb;78:393–410. - PubMed
-
- Høj L, Osterballe O, Bundgaard A, Weeke B, Weiss M. A double-blind controlled trial of elemental diet in severe, perennial asthma. Allergy. 1981May;36:257–262. - PubMed
-
- Imamura H, Nishikawa K, Kishi K, Inoue K, Matsuyama J, Akamaru Y et al. Effects of an Oral Elemental Nutritional Supplement on Post-gastrectomy Body Weight Loss in Gastric Cancer Patients: A Randomized Controlled Clinical Trial. Ann Surg Oncol. 2016Sep;23:2928–2935. - PubMed
-
- Shichinohe T, Sasaki T, Kitashiro S, Morita T, Ono K, Senmaru N et al. Impact of elemental diet on early recovery after laparoscopic colectomy: findings of a randomized controlled trial. Surg Today. 2017Feb;47:166–173. - PubMed
Publication types
MeSH terms
LinkOut - more resources
Full Text Sources
